
    
      Patients with severe refractory ulcerative colitis (UC) or those who received placebo in
      study F506-CL-1107 study can participate in this study. Patients will receive tacrolimus for
      a maximum of 12 weeks in an open-label study manner. Improvement of Disease Activity Index
      (DAI) score and other efficacy scores will be evaluated during the drug administration
      period.
    
  